• Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

    3 days ago - By San Diego Biotechnology

    CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-C, a new global Phase 3 study of lumasiran, an investigational, subcutaneo......
    Read more ...